Next Article in Journal
The Effect of Probiotic Supplementation on the Gut–Brain Axis in Psychiatric Patients
Next Article in Special Issue
Insights into Advanced Neurological Dysfunction Mechanisms Following DBS Surgery in Parkinson’s Patients: Neuroinflammation and Pyroptosis
Previous Article in Journal
Physiological and Biochemical Properties of Cotton Seedlings in Response to Cu2+ Stress
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
CIMB
Volume 45
Issue 5
10.3390/cimb45050259
cimb-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Effect of Ethanol Extract from Mesua ferrea Linn Flower on Alzheimer’s Disease and Its Underlying Mechanism

by
Kusawadee Plekratoke
1,
Chantana Boonyarat
2,
Orawan Monthakantirat
2,
Natsajee Nualkaew
2,
Jinda Wangboonskul
3,
Suresh Awale
4,
Yaowared Chulikhit
2,
Supawadee Daodee
2,
Charinya Khamphukdee
2,
Suchada Chaiwiwatrakul
5 and
Pornthip Waiwut
6,*
1
Biomedical Science Program, Graduate School, Khon Kaen University, Khon Kaen 40002, Thailand
2
Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand
3
Faculty of Pharmaceutical Sciences, Thummasart University, Bangkok 10330, Thailand
4
Division of Natural Drug Discovery, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan
5
Department of English, Faculty of Humanities and Social Sciences, Ubon Ratchathani Rajabhat University, Ubon Ratchathani 34000, Thailand
6
Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Ubon Ratchathani 34190, Thailand
*
Author to whom correspondence should be addressed.
Curr. Issues Mol. Biol. 2023, 45(5), 4063-4079; https://doi.org/10.3390/cimb45050259
Submission received: 28 March 2023 / Revised: 27 April 2023 / Accepted: 3 May 2023 / Published: 6 May 2023
(This article belongs to the Special Issue Molecular Mechanism and Regulation in Neuroinflammation)
Browse Figures
Versions Notes

Abstract

:
The effects of Mesua ferrea Linn flower (MFE) extract on the pathogenic cascade of Alzheimer’s disease (AD) were determined by an in vitro and cell culture model in the search for a potential candidate for the treatment of AD. The 2,2′-azino-bis-3-ethylbenzthiazoline-6-sulphonic acid (ABTS) and 1,1-diphenyl-2-picrylhydrazyl (DPPH) assay exhibited that the MFE extract had antioxidant activities. According to the Ellman and the thioflavin T method’s result, the extracts could inhibit acetylcholinesterase and β-amyloid (Aβ) aggregation. Studies on neuroprotection in cell culture found that the MFE extract could reduce the death of human neuroblastoma cells (SH-SY5Y) caused by H2O2 and Aβ. Western blot analysis exhibited that the MFE extract alleviated H2O2-induced neuronal cell damage by downregulating the pro-apoptotic proteins, including cleaved caspase-3, Bax, and by enhancing the expression of anti-apoptotic markers including MCl1, BClxl, and survivin. Moreover, MFE extract inhibited the expression of APP, presenilin 1, and BACE, and increased the expression of neprilysin. In addition, the MFE extract could enhance scopolamine-induced memory deficit in mice. Overall, results showed that the MFE extract had several modes of action related to the AD pathogenesis cascade, including antioxidants, anti-acetylcholinesterase, anti-Aβ aggregation, and neuroprotection against oxidative stress and Aβ. Therefore, the M. ferrea L. flower might be a possibility for further development as a medication for AD.

1. Introduction

Alzheimer’s disease (AD) is a neurodegenerative disorder causing dementia that is related to cognition and memory. The most common sites of pathology are the hippocampus and cerebral cortex [1]. According to World Alzheimer’s Report 2018, dementia cases including AD were estimated to be 50 million worldwide. Furthermore, they were likely to be doubled by 2030 and triple by 2050. In 2018, twenty people turned out to be diagnosed with dementia every minute. Dementia globally cost 1 trillion US dollars in 2018 and was anticipated to reach 2 trillion US dollars in 2030 [2]. The pathogenesis of AD is not yet fully understood, but the scientific consensus is certain that it is a complex disease brought on by various factors. These include aggregation of Aβ, deposition of neurofibrillary tangles (NFTs), deficiency of cholinergic neurotransmission, oxidative stress, and neuroinflammation. It has been shown that simultaneous cholinergic importance plays a role in the development of AD. Acetylcholine (ACh), which is crucial for cognitive function, is present in decreased concentrations and functions in AD patients. These anomalies, such as cholinergic neuron loss and decreased acetylcholinesterase activity, lend support to the cholinergic theory of AD [3]. In the aging brain, misfolded protein accumulates and leads to metabolic loss, oxidative stress-induced damage, and synapse dysfunction. Oxidative damage in AD is indicated by high levels of DNA oxidation products in mitochondria and nuclei [4,5]. Presently, the US Food and Drug Administration (FDA) has approved five drugs in three sub-classes for the treatment of AD including acetylcholinesterase (AChE) inhibitor (rivastigmine, galantamine, and donepezil), N-methyl D aspartate receptor (NMDA) antagonist (memantine), and a combined drug between AChE inhibitor and NMDA receptor antagonist (Namzaric®) [6]. However, the single target drug benefits in only the palliative treatment but has no effect of curing or preventing AD. Due to AD having several etiologies, the conventional strategy of modifying one target may not be enough to treat this complicated disease. Nowadays, a great source for potential therapies in various complex diseases is natural products such as herbs and plants. Therefore, it should be of great interest to find a new potential drug from natural products for AD treatment.
Mesua ferrea Linn, a species in Calophyllaceae family, is widely distributed in tropical countries such as India, Thailand, China, and New Guinea. Some important ayurvedic formulations contain M. ferrea L. such as Brahma rasayana, which can enhance cognitive function and improve memory [7]. Several studies showed that the M. ferrea L. exhibits several therapeutic actions including antioxidant [8], anti-microbial [9], anti-cancer [10], and anti-inflammation [11]. In addition, the crude extract of M. ferrea L. flower exhibits activities related to the pathogenesis of AD, which includes antioxidant [12] and anti-inflammation [11]. Several phytochemical studies have shown that the major chemical components of M. ferrea L. are phenolic compounds [13], flavonoids [13], coumarins [14], and xanthones [15]. From the literature review, these components are naturally occurring phytochemicals with heterocyclic structures that display a wide range of biological activities related to AD including anti-acetylcholinesterase, anti-Aβ aggregation, antioxidant, and anti-inflammation. Therefore, the aim of this study is to investigate the potential of MFE extract as an AD treatment. The MFE extract was investigated for the activities associated with AD including antioxidant, AChE function, Aβ aggregation, and neuroprotection. To clarify the mechanism of action, the expression levels of proteins involved with AD pathogenesis were determined by Western blotting analysis. Finally, the effects of the MFE extract on cognitive function were evaluated in a scopolamine-induced cognitive-deficit animal model.

2. Materials and Methods

2.1. Chemicals and Reagents

The flower powder of M. ferrea L. was offered by Chao Phya Abhaibhubejhr Hospital, Prachinburi Province, Thailand. The plant was identified by Benjawan Leenin, chief of the Traditional Knowledge Center, Chao Phya Abhaibhubejhr Hospital Foundation. The voucher specimen was deposited at the museum of Chao Phya Abhaibhubejhr Hospital. Quercetin, gallic acid, trolox, acetylthiocholine iodide (ATCI), tacrine, Aβ1–42, N-acetyl cysteine (NAC), Dulbecco’s modified Eagle medium nutrient mixture F-12 (DMEM/F12) trypsine, and fetal bovine serum (FBS), were purchased from Gibthai (GT Chemical supplies Co., Ltd., Bangkok, Thailand), Sigma-Aldrich (SM Chemical supplies Co., Ltd., Bangkok, Thailand), Fluka (SM Chemical supplies Co., Ltd., Bangkok, Thailand), and Merck (Merck, Bangkok, Thailand).

2.2. Plant Extraction

The flower powder of M. ferrea L. (3 kg) was extracted with ethanol for 7 days at room temperature. Then, the extract was dried in a rotary evaporator at reduced pressure at 45 °C after filtering to give the crude extract and kept in a refrigerator at 4 °C until needed for analysis.

2.3. Determination of the Total Phenolic and Flavonoid Contents

2.3.1. Determination of the Total Phenolic Content

The total phenolic content was assessed using the Folin–Ciocalteu test. The method was performed as described by Blainski with minor modifications. Briefly, the MFE extract was dissolved with ethanol and added with 10% Folin–Ciocalteu reagent. Then, the mixture was added with 7.5% Na2CO3 and incubated for 2 h. After that, the absorbance of the mixture was detected at 700 nm. Total phenolic content was exhibited as gallic acid equivalents per milligram of extract (µg of GAE/mg) [16].

2.3.2. Determination of the Total Flavonoid Content

Total flavonoid content using quercetin as standard. The assay was performed as described by Chang with minor modifications. The assay was carried out in 96-well plate by mixing the following: ethanol extract, 25 g/L of AlCl3, and 100 g/L of CH3COONa. The mixture solution was incubated for 15 min. After incubation, the absorbance of the mixture solution was measured at 450 nm. The results were presented as quercetin equivalents per milligram of extracts (µg of QC/mg) [17].

2.4. In Vitro Assay for Activities Related to AD Pathogenesis

2.4.1. Antioxidant Activity by DPPH and ABTS Assay

The DPPH assay was performed as directed by Songsiang. Briefly, 100 µL of the MFE extract was combined with 100 µL of 0.2 mM DPPH solution at room temperature for 30 min. After incubation, using a microplate reader, the absorbance was measured at 550 nm. The activity of the MFE extract to scavenge free radicals was evaluated by comparing its absorbance with that of a control. Antioxidant standard used was trolox [18].
The 2,2′-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS•+) radical cation was decolonized to measure the antioxidant activity. The reaction of 7 mM ABTS with 2.45 mM potassium persulfate in water at ambient temperature and darkness for 12–16 h generated the ABTS•+. The ABTS•+ solution was diluted with ethanol prior to the experiment to obtain an absorbance of 0.70 ± 0.02 at 700 nm. In the experiment, the MFE extract (50 µL) was added to react with ABTS•+ solution (100 µL) for 15 min. After incubation, a measurement of the solution’s absorbance was performed at the wavelength of 700 nm. As a standard for antioxidants, trolox was used [19].

2.4.2. Acetylcholinesterase Inhibitory Activity Assay

The MFE extract was evaluated for acetylcholinesterase (AChE) inhibitory activity by using the modified Ellman’s method. The experiment was prepared in 96-well plate by mixture with 25 μL of the MFE extract or standard (tacrine), 25 μL of 1 mM acetylthiocholine iodide (ATCI), 125 μL of 1 mM 5, 5′-dithiobis-(2 nitrobenzoic acid) (DTNB), and 50 μL of 0.2 U/mL AChE form an electric eel (type VI-S), respectively. The absorbance of enzyme activity was measured using the microplate reader at 405 nm and detected every 30 s for 5 min [20].

2.4.3. Amyloid Aggregation Inhibitory Activity Assay

The MFE extract was investigated for anti-Aβ aggregation by using the thioflavin-T (ThT) assay. Briefly, 2 µL of the MFE extract or standard (curcumin) was incubated with 18 µL of 10 µM Aβ1–42 in 0.5 M phosphate buffer (pH 7.4) for 48 h at 37 °C. After incubation, 180 µL of 5 µM ThT in a glycine/NaOH solution (pH 8) was added to the sample and incubated for 5 min. Then, the fluorescence intensities in each well were recorded at wavelengths of 446 nm (excitation) and 490 nm (emission) using a fluorescence spectrophotometer [21].

2.5. Neuroprotective Activities Assay

Neuroblastoma cells (SH-SY5Y) were cultured in DMEM/F12 supplemented with 10% FBS in a humidified 5% CO2 incubator at 37 °C. SH-SY5Y cells were regularly cultured in a cell culture flask of 75 cm2 for 24 h. After that, the cells were added with 1% FBS in a culture medium and supplemented with 10 μM RA for 6 days to differentiate neural cells. The media replenished with RA were changed every 3 days [22]. Before testing, cells were plated in 96-well plates at a density of 5 × 105 cells/mL and given an additional 48 h of incubation. The neuroprotective effect of MFE extract against H2O2-induced cell damage was determined using the cell-based assay. The differentiated SH-SY5Y cells were pretreated with the extract or standard (n-acetylcysteine, NAC) for 2 h. Then, cells were induced by 250 µM H2O2 for 2 h to generate oxidative stress conditions. The cell viability was determined by incubating the cells with 0.5 mg/mL MTT for 2 h and measured by a microplate reader at 550 nm [23].
For investigation of the neuroprotective effect against Aβ1–42-induced cell damage, preparing for the Aβ1–42 was modified from Takomthong et al. Aβ1–42 that had been lyophilized was reconstituted in PBS at a concentration of 250 μM and kept at −20 °C until analysis. Aliquots were diluted to a final concentration of 25 µM using a culture-free serum medium and incubated at 37 °C for 72 h to generate aggregated amyloid. For assays, the cells were incubated with MFE extract or standard (curcumin) for 2 h and after that, induced with aggregated 25 µM of Aβ1–42 for 24 h. The cell viability was evaluated by MTT assay [23].

2.6. Effect on the Expression of AD- and Apoptosis-Related Proteins in the SH-SY5Y Cells

The differentiated SH-SY5Y cells were plated into a 6-well plate at a concentration of 1 × 106 cell/mL for 48 h. Then, the cells were treated with MFE extract or standard (NAC) for 2 h. After that, the cells were induced with 250 µM of H2O2 for 8 min. Regarding the procedure for lysing cells, lysis buffer was added to the treated cells for 30 min. The lysate was centrifuged for 10 min at 4 °C at 13,500 rpm, and the supernatants were collected. After that, the Bradford test was used to measure the total protein content. The SDSPAGE method was used to separate proteins and transferred them to a polyvinylidene difluoride (PVDF) membrane. The membrane was probed with primary antibodies including APP, presenilin 1, beta-site APP cleaving enzyme (BACE), neprilysin, survivin, bax, bcl-xl, mcl-1, cleave caspase 3, and actin. After that, secondary antibodies were allowed to incubate on the membranes. Finally, the technology for enhanced chemiluminescence was used to see the membranes [24].

2.7. The Effects of MFE Extract on Scopolamine-Induced Memory Impairments in Mice

The mice ICR 6 weeks old weighing between 30 and 35 g were derived from the Northeast Laboratory Animal Center, Khon Kaen University. All animal experiments were approved by the Institutional Animal Care and Use Committee of Khon Kaen University, based on the Ethic of Animal Experimentation of National Research Council of Thailand (approval number: IACUC-KKU-4/66). Before testing, the mice were kept in an environment with an ambient temperature of 25 °C, and a humidity level of 50–55%, under a cycle of 12 h of light and 12 h of darkness. Animals had unrestricted access to food and water.
The effect of MFE extract on scopolamine-induced memory deficits in mice was determined using Y-maze and water maze tests which were behavioral models. The mice were fed with MFE extract (50, 250, and 500 mg/kg/day) or reference standard donepezil (3 mg/kg/day) by oral administration for 7 days. The mice were investigated for behavioral changes in learning and memory. For both experiments, the animals received the test compounds for 1 h before scopolamine injection. After oral administration, the mice were induced with scopolamine (1 mg/kg) via intraperitoneal (i.p.) for behavioral changes in learning and memory. After thirty minutes, the animals were determined for memory deficit using Y-maze and water maze tests.
The Y-maze test, the Y-maze apparatus, was made of black polypropylene with three equally spaced arms at a 120 angle from each other. Each arm was 40 cm in length, 12 cm in height, 10 and 3 cm in width at the top and bottom, respectively. All mice were placed in the Y-maze apparatus and allowed to run freely through the apparatus for 8 min. After each passage, alcohol (70% ethanol) was used to disinfect the apparatus to completely get rid of the smelly residue the previous mouse left behind. The percentage of alternation was calculated by the manually recorded total number of arm entries and the sequence of entries. The consecutive visits into all three arms without repeated entries were identified as the alternation behavior. The alternation was represented as the ratio of alternation to possible alternation multiplied by 100 [24].
The Morris Water Maze test was used to measure spatial memory. The water maze used a black round pool (70 cm in diameter and 28 cm high). The pool was filled with water (25 °C) and comprised four quadrants (Q1–Q4). At the middle of one quadrant (Q1), the removable platform was immersed 1 cm under the water surface. In the training phase, the mice were trained to memorize the location of platform. The mice were placed in quadrants (Q1–Q4) of the pool and given 1 min to swim around in find of the platform. The time that the mice spent to reach the top of platform was recorded as the escape latency. All animals were performed four tests every day for five straight days. In the test phase, each animal was released to swim in the pool without the platform for 1 min from each quadrant. The time that the animal spent in the area that previously contained the platform (Q1) was recorded as the retention time [24].

2.8. HPLC Analysis and Validation of the Analytical Method

The HPLC analysis of the phenolic acid and flavonoids were performed with Dionex Ultimate 3000 liquid chromatograph (Germany) using a C18 column (4.6 mm 250 mm) packed with 5 mm diameter particles under gradient conditions. The flow rate of the mobile phase was 0.7 mL/min and consisted of a mixture of solvents: A (acetonitrile) and B (1% aq. acetic acid). The gradient elution was changed from 40% to 60% A in 39 min, and from 60% to 90% B in 50 min. The composition of the mobile phase was restored to its initial condition (solvent A: solvent B: 10: 90) in 55 min. The wavelengths used were 272 nm for gallic acid, ferulic acid, p-coumaric acid, catechin, rutin, and quercetin. Before use, the mobile phase and sample were degassed with an ultrasonic bath after being filtered through a membrane filter at 0.45 m. A concentration range of 5–200 µg/mL of standard stock solutions was prepared in the HPLC mobile phase. The retention time was compared to standards to validate the chromatography peaks [25].

2.9. Statistical Analyses

The data were represented as means ± SD (n = 5) for in vitro and means ± SEM (n = 6) for in vivo experiments. Statistical significance was evaluated by student t-test or one-way analysis of variance (ANOVA). For all statistical analyses, a p-value < 0.05 was considered significant.

3. Results

3.1. In Vitro Assay for Activities Related to AD Pathogenesis

The effects of MFE extract on the pathogenic cascade of AD were examined by an in vitro model in the search for a potential candidate for treatment of AD. The total phenolic content and the total flavonoids content of the MFE extract were 109.59 ± 2.12 gallic acid equivalent/g and 43.77 ± 5.92 quercetin equivalent/g. The ABTS and DPPH assays exhibited that the MFE extract had an ability to scavenge ABTS and DPPH radicals with IC50 values of 85.28 ± 3.22 and 35.33 ± 0.65 µg/mL, respectively. The acetylcholinesterase inhibitory action was evaluated by using Ellman’s method. The results showed that the MFE extract possessed acetylcholinesterase inhibitory activity with IC50 value of 242.49 ± 3.53 µg/mL. Regarding the study of the effect on Aβ aggregation, it was indicated that the MFE extract inhibited Aβ aggregation with IC50 value of 39.73 ± 1.72 µg/mL. The results were presented in Table 1.

3.2. Neuroprotection against Oxidative Stress

The MFE extract was evaluated for cytotoxicity on SHSY-5Y cells. The cells were treated with the MFE extract at concentrations of 0.1, 1, 10, and 100 μg/mL for 2 h. The results showed that the MFE extract at the concentration of 0.1–10 μg/mL was non-toxic to SHSY-5Y cells. In order to evaluate the neuroprotective effects in SH-SY5Y cells against cell damage induced by H2O2, the cells were incubated with MFE extract at concentrations of 0.01, 0.1, 1, and 10 μg/mL. After incubation for 2 h, the cells were incubated with 250 μM H2O2 for 2 h. The results exhibited that the MFE extract at a concentration of 10 μg/mL significantly inhibited H2O2-induced neuronal cell death when compared with only the H2O2-treated group (Figure 1).

3.3. Neuroprotection against Aβ1–42 Toxicity

The neuroprotective ability of the MFE extract was investigated by using Aβ1–42 peptide-induced toxicity in SH-SY5Y cells. The MFE extract showed a neuroprotective effect against Aβ1–42 peptide-induced neurotoxicity. The SH-SY5Y cells were pretreated with the MFE extract before Aβ1–42 exposure. The results showed that the MFE extracts at concentrations of 1 and 10 μg/mL significantly decreased the cell viability loss generated by the Aβ1–42 peptide (Figure 2).

3.4. The Effect on the Expression of AD- and Apoptosis-Related Proteins

The investigation of the protective mechanisms of the MFE extract against H2O2-induced cell damage in the SH-SY5Y cell was performed by using Western blot analysis. The cells treated with H2O2 alone could increase protein levels of amyloid precursor protein (APP), presenilin 1, beta-site APP cleaving enzyme (BACE), Bax, MCl-1, cleaved caspase-3, and decreased expression protein of neprilysin, BCl-xl, and survivin. On the other hand, pretreatment with MFE extract prior to H2O2 downregulated expression of the pro-apoptotic proteins including cleaved caspase-3 and Bax, while increasing protein levels of MCl-1, BCl-xl, and survivin. In addition, the cells were treated with the MFE extract before the H2O2 insult, which resulted in an increased protein level of neprilysin and decreased expression of APP, BACE, and presenilin 1. Therefore, the MFE extract showed an ability to protect neuronal damage induced by oxidative stress via the modulating functions of the proteins involved in apoptosis and amyloidogenic pathways (Figure 3).

3.5. The Effects of the MFE Extract on Scopolamine-Induced Memory Impairments in Mice

A Y-maze test was performed to test short-term spatial working memory. After seven days of MFE treatment, the percentage of alternation behavior was assessed. The result exhibited that the mice in the scopolamine-treated group decrease alternation percentage when compared with the vehicle-treated control group (p < 0.01), and the decreased alternation induced by scopolamine (1 mg/kg) was significantly reversed by the MFE extract at dose 500 mg/kg/day (p < 0.01) (Figure 4). The result indicated that the flower extract of M. ferrea L. enhanced working memory in mice with scopolamine-induced impairment.
The Morris Water Maze (MWM) task was carried out to evaluate the hippocampus-dependent spatial-learning ability. MWM was performed to test long-term memory. Determination of the effect of the MFE extract on scopolamine-induced memory impairment was performed after the mice had been received with MFE extract for seven days. The result exhibited that the mice in the control group spent significantly longer time in quadrant 1 (Q1) than mice in the scopolamine-treated group. The mice that were pretreated with reference standard donepezil (3 mg/kg) significantly improved cognitive deficits indicated by the mice spending longer time in the quadrant (Q1) than the scopolamine-treated mice. In addition, the mice injected with the MFE extract at a dose of 250 and 500 mg/mL also spent significantly more time in the target quadrant than the scopolamine-treated group (Figure 5). The result exhibited that the MFE extract could improve long-term memory in mice with scopolamine-induced amnesia.

3.6. HPLC Analysis of the Constituents of the MFE Extract and the Validation Method

Gallic acid, p-coumaric acid, catechin, rutin, ferulic acid, and quercetin were utilized as markers in the HPLC analysis of the MFE extract. Six different concentrations of standard solutions, i.e., 5–30 µg/mL for gallic acid, 10–60 µg/mL for p-coumaric acid, rutin, ferulic acid, and quercetin, 20–100 µg/mL for catechin, were used. The range, linearity, LOD, LOQ, precision, and accuracy of the HPLC technique were determined as validation parameters. The validation results revealed good linearity with the coefficient of determination (r2) greater than 0.99, high precision with low percentage relative standard deviation and good accuracy with percentage recovery rates within 90–110%. Thus, the developed HPLC method is appropriate for the analysis of the six chemicals in the MFE extract (Table 2). The HPLC method was used to determine the amount of gallic acid, coumaric acid, catechin, rutin, ferulic acid, quercetin in the crude extract, and the retention time shown in Figure 6 was consistent with the standard solutions and the MFE extract. The amount of gallic acid, coumaric acid, catechin, rutin, ferulic acid, and quercetin in the MFE extract were 13.17 µg/mg extract, 17.18 µg/mg extract, 2.73 µg/mg extract, 3.06 µg/mg extract, 1.91 µg/mg extract, and 0.34 µg/mL, respectively.

4. Discussion

Several phytochemical studies have shown that the chemical components of M. ferrea L. flower are phenolic acid [13], flavonoid [13], coumarin [14] and xanthone [13,15]. A previous study reported the anti-AD action of phenolic acids which prevented the development of AD pathology by inhibiting the Aβ aggregation pathway [26]. Flavonoids have been revealed to possess multiple biological activities related to AD pathology including anti-acetylcholinesterase, anti-Aβ aggregation, antioxidant, and anti-inflammation [27]. In this study, the flavonoids (rutin, catechin, quercetin) and phenolic acids (gallic acid, ferulic acid, p-coumaric acid) in MFE extract were quantified by using HPLC. Several studies have shown that these compounds exhibited antioxidant [28,29,30], anti-AChE function [31,32,33], anti-Aβ aggregation [34,35,36,37,38], and neuroprotection [39,40,41,42]. Our HPLC results showed that the major phenolic acids found in the MFE extract were p-coumaric acid and gallic acid, while the major flavonoid was rutin. Previous studies have showed that p-coumaric acid and gallic acid possessed neuroprotective action against Aβ toxicity [38,40].
The cholinergic system is well known to be important for a variety of cognitive functions [43]. According to evidence, cognitive impairment in AD is associated with a deterioration of acetylcholine (ACh) transmission, which plays important roles in learning and memory functions [44]. Cholinergic transmission is terminated when ACh is hydrolyzed by AChE. Thus, AChE inhibition is a crucial target for AD therapy. This study has established that the MFE extract had an ability to inhibit AChE function in a dose-dependent manner. A prior investigation demonstrated that various phenolic acids and flavonoids possessed an AChE inhibitory action [45]. In addition, gallic acid and p-coumaric acid, which are the major components in the MFE extract, showed an ability to inhibit AChE activity [31]. Thus, anti-AChE activity of the MFE might partly come from gallic acid, p-coumaric acid, and rutin, which are the major components found in the extract.
Numerous studies indicated that oxidative damage was found in the brains of patients with AD and may contribute to the onset of AD [46]. The imbalance between the production and the removal of free radicals is reflected in oxidative stress. [47]. Therefore, antioxidant drugs can interrupt the progression of AD by preventing the neurotoxic and damaging consequences of oxidative stress. In this investigation, the MFE extract exhibited antioxidant activities in in vitro models. A prior research approach indicated high correlations between total phenolic, flavonoid content, and radical scavenging activity [48]. Heim and coworkers reported that rutin, catechin, and quercetin showed an ability to scavenge free radicals by an ABTS assay [30]. Several studies revealed that p-coumaric acid, gallic acid, and ferulic acid exhibited antioxidant properties determined by DPPH, ABTS, FRAP, and ORAC [49,50]. From the HPLC analysis, the MFE extract contains various flavonoids (rutin, catechin, quercetin) and phenolic acids (gallic acid, ferulic acid, p-coumaric acid), thus MFE showed an ability to scavenge free radicals via the action of these flavonoids and phenolic components.
The deposit of Aβ plaques in the brains of AD patients is a hallmark of AD pathogenesis. Hence, preventing or lowering the aggregation of Aβ has become the main approach of many therapeutic strategies that have been developed or presently are in clinical trials. A major component of amyloid plaques in AD brains is Aβ1–42. Several studies have shown that Aβ1–42 plays a role in the etiology of AD [51,52]. In addition, the generation of Aβ1–42 was found to increase in familial AD patients [53]. Studies using transgenic mice and in vitro models showed that Aβ1–42 might form amyloid plaques faster than Aβ1-40. So, to evaluate the Aβ aggregation and the Aβ-induced cytotoxicity in SH-SY5Y neuronal cells, we used Aβ1–42. In this study, we used the ThT fluorescence assay to evaluate the effects of MFE extracts on the inhibition of Aβ aggregation. The results exhibited that the MFE extract could inhibit the aggregation of Aβ1–42. Additionally, it has been shown that Aβ is harmful to neurons via a number of mechanisms, including mitochondrial malfunction, ROS production, and apoptosis [54,55]. Thus, the neuroprotective effect of the MFE extract against Aβ1–42 toxicity in SH-SY5Y cells was also investigated in the present study. Our results showed that Aβ1–42 could induce neuronal cell death. This result was consistent with a previous study, indicating that Aβ1–42 at micromolar concentration levels caused neuronal death in culture cells [56]. Pretreatment of the SH-SY5Y cells with the MFE extracts at concentrations of 1 and 10 μg/mL significantly decreased the cell viability loss generated by the Aβ1–42 peptide. Thus, the MFE extract showed a neuroprotective effect against Aβ1–42 peptide-induced neurotoxicity.
Reactive oxygen species (ROS) can destroy neuronal cells via apoptosis. Exogenous ROS sources such as H2O2 are frequently employed to induce apoptosis [57]. A previous report showed etiological associations between neurodegenerative diseases and the production of H2O2 [58]. As a result, H2O2-induced neuronal damage is thought to be a viable model for studying neurodegeneration brought on by oxidative stress [59]. In this study, the vitality of cells exposed to H2O2 was significantly increased by pretreating SH-SY5Y cells with the MFE extract. For neuroprotective action, the antioxidant properties of the MFE extract may contribute to its neuroprotective effects. In addition to the antioxidant effect, the protective effect can result from other mechanisms. Thus, to determine the protective mechanisms of the MFE extract against H2O2-induced cell death, we used Western blot analysis to identify the MFE extract that affected the expression of pro-apoptotic and anti-apoptotic proteins. Pretreatment of SH-SY5Y cells with the MFE extract before H2O2 exposure showed downregulation of the pro-apoptotic proteins including Bax and cleaved caspase-3 and upregulation of the anti-apoptotic proteins including BClxl, MCl1, and survivin. Previous research studies revealed that the mitochondrial apoptotic pathway was associated with oxidative stress-induced neuronal cell death in H2O2-induced SH-SY5Y cells, which was a key mechanism in neurodegenerative diseases [60]. The permeability of the mitochondrial membrane was increased as a result of excessive ROS production, causing cytochrome C to be released. Cytochrome C release stimulates pro-apoptotic factors, such as caspase-3 and causes eventual cell death. Our results indicated that, after being treated with H2O2, proteolytic cleavage of caspase-3 increased and pro-apoptotic proteins of Bax also increased. The MFE extract protected neuronal cells against H2O2-induced death by downregulation of cleaved caspase-3, decreased pro-apoptotic protein of Bax, as well as increased expression of MCl1, BClxl, and survivin. Therefore, the antioxidant and anti-apoptotic properties of the MFE extract appear to prevent neuronal cell death brought on by oxidative stress.
Furthermore, the accumulation of Aβ plaques in AD brains was believed to be partly enhanced by oxidative stress. Several studies had demonstrated the relationship between oxidative stress and Aβ plaques development. Oxidative stress played important roles in the progression of Aβ peptides via the regulation of APP metabolism [61]. According to the amyloid cascade theory, the neurotoxic amyloid peptides that were the hallmark of AD could be produced as a result of the proteolytic cleavage of APP [51]. There are two APP processing pathways, including amyloidogenic or nonamyloidogenic pathways. In the nonamyloidogenic pathway, APP is sequentially cleaved by α- and γ-secretases to generate a soluble small peptide that does not have neurotoxic effects. In the harmful amyloidogenic pathway, the sequential cleavage of APP by β- and γ-secretase promote a long chain insoluble Aβ. The Aβ will aggregate to form an amyloid plaque and accumulate outside the cell resulting in cell death.
In the present study, the effect of the MFE extract on the expression of AD-related proteins was investigated by Western blotting analysis. The expression levels of proteins involving Aβ production (presenilin 1, BACE, and APP) and Aβ clearance (neprilysin) were studied. The neuronal cells induced with only H2O2 were found to result in the upregulation of presenilin 1, BACE, and APP compared to untreated normal cells. However, pretreatment with the MFE extract prior to H2O2 alleviated the expression of presenilin 1, BACE, and APP. Presenilin 1 is a subunit of the γ-secretase. It was considered to play an important role in the production of Aβ from APP to provide Aβ fragments and that its absence or inhibition could decrease the production of Aβ [62]. In AD research, this has been proposed as a potential target for an anti-amyloidogenic strategy [63]. Furthermore, the β-secretase that is involved in the processing of APP to create Aβ includes BACE1 and its homolog, BACE2 [64]. It has been demonstrated that BACE1 is a more powerful inducer of APP cleavage leading to the production of Aβ [65]. In an in vitro model, BACE2 was effective at cleaving APP at the secretase cleavage site [66] and releasing Aβ in mutant transfected cells [67]. Moreover, in a model of transgenic mice with an APP mutation, BACE overexpression accelerated APP processing and resulted in elevated levels of Aβ [68]. This is in line with research showing that AD patients’ brains have increased BACE activity due to the presence of a high Aβ plaque load [69,70]. For the Aβ clearance protein, the expression of neprilysin tended to decrease after H2O2 treatment when compared with the control, whereas the cells treated with the MFE extract prior to the H2O2 led to an increase in neprilysin protein expression. According to the report, neprilysin promoted the hydrolysis of Aβ [71]. Neprilysin protein and mRNA levels were found to be considerably reduced in the hippocampus region of AD patients compared to controls [72]. Therefore, the decrease in neprilysin levels may affect the Aβ clearance ability of neuronal cells, leading to the deposition of Aβ in AD brains [73]. Accordingly, neprilysin protein regulation with the MFE extract revealed that the MFE extract might prevent Aβ accumulation which is partly mediated by clearance of Aβ. Conclusively, our results indicated that the MFE extract could protect neurons by preventing Aβ accumulation via inhibition of Aβ production and acceleration of Aβ clearance.
Subacute toxicity of the ethanolic extract of Mesua ferrea L. flowers in rats showed that at the high dose, it did not have any serious toxicity [74]. In addition, we studied the effect of the MFE extract on memory deficit induced by scopolamine in ICR mice. Scopolamine, a nonselective muscarinic antagonist, is widely used to reduce memory and learning abilities. Scopolamine-induced amnesia is the classical method to study the effects of novel cognition-enhancing drugs in animals [75]. The Y-maze test was used to evaluate short-term memory or working memory by examining the animal’s spontaneous alternation behavior. The mice were eager to explore the new arm of the maze as their normal behavior, rather than going back to the one they have already explored. In contrast, the mice with impaired short-term memory failed to recognize which arm they had already been in that was presented by a decreased spontaneous alternation. The Morris Water Maze was used to test long-term memory. It was widely used to study spatial memory and learning abilities [76]. The mice that spent more time during the testing day in the target quadrant where the platform had been located during the training days, represent an improvement in spatial memory. From this study, memory loss in amnesic mice was significantly induced by scopolamine. The seven-day MFE extract treatment reversed the memory deficit induced by scopolamine. The mice treated with the test compound showed a significantly increased percentage of alternation in the Y-maze test and time spent in the target quadrant (Q1) in the water maze test, illustrating an enhancement in short-term and long-term memories, respectively. According to several studies, scopolamine decreased the effectiveness of the cholinergic system by acting on muscarinic receptors and increasing AChE activity [77]. From an in vitro AChE activity determination, the MFE extract showed AChE inhibitory activity. The MFE extract reversed the effect of scopolamine-induced memory loss, indicating that their mechanisms of action were on the same target. Therefore, the cognitive improvement resulting from the MFE extract treatment was contributed by the AChE inhibitory action.

5. Conclusions

The results of the present study demonstrated that the MFE extract had a variety of mechanisms of action that were directed at various targets in the AD pathogenesis cascade which included free radical scavenging, AChE and Aβ aggregation inhibitory actions, as well as neuroprotection against H2O2 and Aβ toxicity. The MFE extract exhibited neuroprotection via the downregulation of the pro-apoptotic protein, specifically, the following: blocking Bax and caspase-3 cleavage activation while upregulating the following anti-apoptotic proteins: MCl1, BClxl, and survivin. Moreover, the MFE extract might have an ability to inhibit the expression of proteins involving Aβ production (APP, presenilin 1, and BACE) and might accelerate the Aβ clearance protein (neprilysin). Overall, results showed that the MFE extract has several modes of action related to the AD pathogenesis cascade including antioxidants, anti-acetylcholinesterase, anti-Aβ aggregation, and neuroprotection against oxidative stress and Aβ-. In addition, the MFE extract showed an ability to enhance scopolamine-induced memory impairment in mice. Therefore, the M. ferrea L. flower extract might have a potential for further development as a medication for AD.

Author Contributions

Conceptualization, P.W., C.B., N.N., O.M., J.W., S.D., Y.C., C.K. and S.A.; methodology, P.W., K.P. and C.B.; formal analysis, P.W., K.P., J.W., S.C. and C.B.; investigation, K.P., P.W. and C.B.; resources, P.W. and C.B.; writing—original draft preparation, K.P., P.W. and C.B.; writing—review and editing, P.W. and C.B.; project administration, P.W. and C.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Fundamental Fund of Khon Kaen University under the National Science, Research and Innovation Fund; Scholarship for Oversea Graduate Research, Khon Kaen University; Research and Graduate Studies; Research Program, Khon Kaen University; and Ubon Ratchathani University, Thailand.

Institutional Review Board Statement

The study has been reviewed and approved by the Institution Animal Care and Use Committee of Khon Kaen University, based on the Ethic of Animal Experimentation of National Research Council of Thailand. The approval number was IACUC-KKU-4/66.

Informed Consent Statement

Not applicable.

Data Availability Statement

All the data generated or analyzed during this study were included in this published article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Orhan, I.; Şener, B.; Choudhary, M.I.; Khalid, A. Acetylcholinesterase and Butyrylcholinesterase Inhibitory Activity of Some Turkish Medicinal Plants. J. Ethnopharmacol. 2004, 91, 57–60. [Google Scholar] [CrossRef]
  2. Alzheimer’s Disease International; Christina, P. World Alzheimer Report 2018-The State of the Art of Dementia Research: New Frontiers; NEW FRONTIERS; Alzheimer’s Disease International: London, UK, 21 September 2018. [Google Scholar]
  3. Francis, P.T. The Interplay of Neurotransmitters in Alzheimer’s Disease. CNS Spectr. 2005, 10, 6–9. [Google Scholar] [CrossRef] [PubMed]
  4. Chen, X.; Guo, C.; Kong, J. Oxidative Stress in Neurodegenerative Diseases. Neural Regen. Res. 2012, 7, 376–385. [Google Scholar] [CrossRef] [PubMed]
  5. Marde, V.S.; Tiwari, P.L.; Wankhede, N.L.; Taksande, B.G.; Upaganlawar, A.B.; Umekar, M.J.; Kale, M.B. Neurodegenerative Disorders Associated with Genes of Mitochondria. Futur. J. Pharm. Sci. 2021, 7, 66. [Google Scholar] [CrossRef]
  6. Rosini, M.; Simoni, E.; Bartolini, M.; Cavalli, A.; Ceccarini, L.; Pascu, N.; McClymont, D.W.; Tarozzi, A.; Bolognesi, M.L.; Minarini, A.; et al. Inhibition of Acetylcholinesterase, β-Amyloid Aggregation, and NMDA Receptors in Alzheimer’s Disease: A Promising Direction for the Multi-target-Directed Ligands Gold Rush. J. Med. Chem. 2008, 51, 4381–4384. [Google Scholar] [CrossRef]
  7. Joshi, H.; Parle, M. Brahmi rasayana Improves Learning and Memory in Mice. Evid. Based Complement. Altern. Med. 2006, 3, 79–85. [Google Scholar] [CrossRef]
  8. Prasad, D.N.; Rao, B.G.; Rao, E.S.; Rao, T.M.; Praneeth, D.V. Quantification of phytochemical constituents and in-vitro antioxidant activity of Mesua ferrea leaves. Asian Pac. J. Trop. Biomed. 2012, 2, S539–S542. [Google Scholar] [CrossRef]
  9. Mazumder, R.; Dastidar, S.G.; Basu, S.P.; Mazumder, A.; Singh, S.K. Antibacterial potentiality of Mesua ferrea Linn. flowers. Phytother. Res. 2004, 18, 824–826. [Google Scholar] [CrossRef]
  10. Mahavorasirikul, W.; Viyanant, V.; Chaijaroenkul, W.; Itharat, A.; Na-Bangchang, K. Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro. BMC Complement. Altern. Med. 2010, 10, 55. [Google Scholar] [CrossRef]
  11. Nandy, S.; Tiwari, P. Screening of anti-inflammatory activity of Mesua ferrea Linn Flower. Int. J. Biomed. Res. 2012, 3, 245–252. [Google Scholar] [CrossRef]
  12. Garg, S.; Sharma, K.; Ranjan, R.; Attri, P.; Mishra, P. In Vivo Antioxidant Activity and Hepatoprotective Effects of Methanolic Extract of Mesua Ferrea Linn. Int. J. PharmTech Res. 2009, 1, 1692–1696. [Google Scholar]
  13. Manse, Y.; Sakamoto, Y.; Miyachi, T.; Nire, M.; Hashimoto, Y.; Chaipech, S.; Pongpiriyadacha, Y.; Morikawa, T. Antiallergic Properties of Biflavonoids Isolated from the Flowers of Mesua ferrea Linn. Separations 2022, 9, 127. [Google Scholar] [CrossRef]
  14. Roy, S.K.; Kumari, N.; Pahwa, S.; Agrahari, U.C.; Bhutani, K.K.; Jachak, S.M.; Nandanwar, H. NorA efflux pump inhibitory activity of coumarins from Mesua ferrea. Fitoterapia 2013, 90, 140–150. [Google Scholar] [CrossRef]
  15. Chukaew, A.; Saithong, S.; Chusri, S.; Limsuwan, S.; Watanapokasin, R.; Voravuthikunchai, S.P.; Chakthong, S. Cytotoxic xanthones from the roots of Mesua ferrea L. Phytochemistry 2019, 157, 64–70. [Google Scholar] [CrossRef] [PubMed]
  16. Blainski, A.; Lopes, G.C.; De Mello, J.C.P. Application and Analysis of the Folin Ciocalteu Method for the Determination of the Total Phenolic Content from Limonium brasiliense L. Molecules 2013, 18, 6852–6865. [Google Scholar] [CrossRef] [PubMed]
  17. Chang, C.-C.; Yang, M.-H.; Wen, H.-M.; Chern, J.-C. Estimation of total flavonoid content in propolis by two complementary colometric methods. J. Food Drug Anal. 2020, 10, 3. [Google Scholar] [CrossRef]
  18. Songsiang, U.; Thongthoom, T.; Zeekpudsa, P.; Kukongviriyapan, V.; Boonyarat, C.; Wangboonskul, J.; Yenjai, C. Antioxidant activity and cytotoxicity against cholangiocarcinoma of carbazoles and coumarins from Clausena harmandiana. ScienceAsia 2012, 38, 75. [Google Scholar] [CrossRef]
  19. Arnao, M.B.; Cano, A.; Acosta, M. The hydrophilic and lipophilic contribution to total antioxidant activity. Food Chem. 2001, 73, 239–244. [Google Scholar] [CrossRef]
  20. Ellman, G.L.; Courtney, K.D.; Andres, V., Jr.; Featherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88–95. [Google Scholar] [CrossRef]
  21. Levine, H. Thioflavine T interaction with synthetic Alzheimer’s diseaseβ-amyloid peptides: Detection of amyloid aggregation in solution: Thioflavine T Fluorescence with β/A4 Peptides. Protein Sci. 1993, 2, 404–410. [Google Scholar] [CrossRef]
  22. de Medeiros, L.M.; De Bastiani, M.A.; Rico, E.P.; Schonhofen, P.; Pfaffenseller, B.; Wollenhaupt-Aguiar, B.; Grun, L.; Barbé-Tuana, F.; Zimmer, E.R.; Castro, M.A.A.; et al. Cholinergic Differentiation of Human Neuroblastoma SH-SY5Y Cell Line and Its Potential Use as an In vitro Model for Alzheimer’s Disease Studies. Mol. Neurobiol. 2019, 56, 7355–7367. [Google Scholar] [CrossRef] [PubMed]
  23. Takomthong, P.; Waiwut, P.; Yenjai, C.; Sombatsri, A.; Reubroycharoen, P.; Lei, L.; Lai, R.; Chaiwiwatrakul, S.; Boonyarat, C. Multi-Target Actions of Acridones from Atalantia monophylla towards Alzheimer’s Pathogenesis and Their Pharmacokinetic Properties. Pharmaceuticals 2021, 14, 888. [Google Scholar] [CrossRef] [PubMed]
  24. Chheng, C.; Waiwut, P.; Plekratoke, K.; Chulikhit, Y.; Daodee, S.; Monthakantirat, O.; Pitiporn, S.; Musigavong, N.; Kwankhao, P.; Boonyarat, C. Multitarget Activities of Kleeb Bua Daeng, a Thai Traditional Herbal Formula, Against Alzheimer’s Disease. Pharmaceuticals 2020, 13, 79. [Google Scholar] [CrossRef]
  25. Seal, T. Quantitative HPLC analysis of phenolic acids, flavonoids and ascorbic acid in four different solvent extracts of two wild edible leaves, Sonchus arvensis and Oenanthe linearis of North-Eastern region in India. J. Appl. Pharm. Sci. 2016, 6, 157–166. [Google Scholar] [CrossRef]
  26. Hamaguchi, T.; Ono, K.; Murase, A.; Yamada, M. Phenolic Compounds Prevent Alzheimer’s Pathology through Different Effects on the Amyloid-β Aggregation Pathway. Am. J. Pathol. 2009, 175, 2557–2565. [Google Scholar] [CrossRef]
  27. Li, J.; Sun, M.; Cui, X.; Li, C. Protective Effects of Flavonoids against Alzheimer’s Disease: Pathological Hypothesis, Potential Targets, and Structure–Activity Relationship. Int. J. Mol. Sci. 2022, 23, 10020. [Google Scholar] [CrossRef]
  28. Kumar, N.; Goel, N. Phenolic acids: Natural versatile molecules with promising therapeutic applications. Biotechnol. Rep. 2019, 24, e00370. [Google Scholar] [CrossRef]
  29. Jiménez-Aliaga, K.; Bermejo-Bescós, P.; Benedí, J.; Martín-Aragón, S. Quercetin and rutin exhibit antiamyloidogenic and fibril-disaggregating effects in vitro and potent antioxidant activity in APPswe cells. Life Sci. 2011, 89, 939–945. [Google Scholar] [CrossRef]
  30. Heim, K.E.; Tagliaferro, A.R.; Bobilya, D.J. Flavonoid antioxidants: Chemistry, metabolism and structure-activity relationships. J. Nutr. Biochem. 2002, 13, 572–584. [Google Scholar] [CrossRef]
  31. Szwajgier, D.; Borowiec, K. Phenolic Acids from Malt Are Efficient Acetylcholinesterase and Butyrylcholinesterase Inhibitors: Phenolic Acids as Efficient AChE and BChE Inhibitors. J. Inst. Brew. 2012, 118, 40–48. [Google Scholar] [CrossRef]
  32. Guo, A.J.; Xie, H.Q.; Choi, R.C.; Zheng, K.Y.; Bi, C.W.; Xu, S.L.; Dong, T.T.; Tsim, K.W. Galangin, a flavonol derived from Rhizoma Alpiniae Officinarum, inhibits acetylcholinesterase activity in vitro. Chem. Biol. Interact. 2010, 187, 246–248. [Google Scholar] [CrossRef]
  33. Okello, E.J.; Mather, J. Comparative Kinetics of Acetyl- and Butyryl-Cholinesterase Inhibition by Green Tea Catechins|Relevance to the Symptomatic Treatment of Alzheimer’s Disease. Nutrients 2020, 12, 1090. [Google Scholar] [CrossRef] [PubMed]
  34. Yu, M.; Chen, X.; Liu, J.; Ma, Q.; Zhuo, Z.; Chen, H.; Zhou, L.; Yang, S.; Zheng, L.; Ning, C.; et al. Gallic acid disruption of Aβ1–42 aggregation rescues cognitive decline of APP/PS1 double transgenic mouse. Neurobiol. Dis. 2018, 124, 67–80. [Google Scholar] [CrossRef] [PubMed]
  35. Bramanti, E.; Fulgentini, L.; Bizzarri, R.; Lenci, F.; Sgarbossa, A. β-Amyloid Amorphous Aggregates Induced by the Small Natural Molecule Ferulic Acid. J. Phys. Chem. B 2013, 117, 13816–13821. [Google Scholar] [CrossRef] [PubMed]
  36. Wang, S.-W.; Wang, Y.-J.; Su, Y.-J.; Zhou, W.-W.; Yang, S.-G.; Zhang, R.; Zhao, M.; Li, Y.-N.; Zhang, Z.-P.; Zhan, D.-W.; et al. Rutin inhibits β-amyloid aggregation and cytotoxicity, attenuates oxidative stress, and decreases the production of nitric oxide and proinflammatory cytokines. Neurotoxicology 2012, 33, 482–490. [Google Scholar] [CrossRef]
  37. Xie, H.; Wang, J.-R.; Yau, L.-F.; Liu, Y.; Liu, L.; Han, Q.-B.; Zhao, Z.; Jiang, Z.-H. Catechins and Procyanidins of Ginkgo biloba Show Potent Activities towards the Inhibition of β-Amyloid Peptide Aggregation and Destabilization of Preformed Fibrils. Molecules 2014, 19, 5119–5134. [Google Scholar] [CrossRef]
  38. Andrade, S.; Loureiro, J.A.; Pereira, M.D.C. Influence of in vitro neuronal membranes on the anti-amyloidogenic activity of gallic acid: Implication for the therapy of Alzheimer’s disease. Arch. Biochem. Biophys. 2021, 711, 109022. [Google Scholar] [CrossRef] [PubMed]
  39. Lu, Z.; Nie, G.; Belton, P.S.; Tang, H.; Zhao, B. Structure–activity relationship analysis of antioxidant ability and neuroprotective effect of gallic acid derivatives. Neurochem. Int. 2006, 48, 263–274. [Google Scholar] [CrossRef]
  40. Yoon, J.-H.; Youn, K.; Ho, C.-T.; Karwe, M.V.; Jeong, W.-S.; Jun, M. p-Coumaric Acid and Ursolic Acid from Corni fructus Attenuated β-Amyloid25–35-Induced Toxicity through Regulation of the NF-κB Signaling Pathway in PC12 Cells. J. Agric. Food Chem. 2014, 62, 4911–4916. [Google Scholar] [CrossRef]
  41. Kikugawa, M.; Tsutsuki, H.; Ida, T.; Nakajima, H.; Ihara, H.; Sakamoto, T. Water-soluble ferulic acid derivatives improve amyloid-β-induced neuronal cell death and dysmnesia through inhibition of amyloid-β aggregation. Biosci. Biotechnol. Biochem. 2016, 80, 547–553. [Google Scholar] [CrossRef]
  42. Bastianetto, S.; Yao, Z.-X.; Papadopoulos, V.; Quirion, R. Neuroprotective effects of green and black teas and their catechin gallate esters against β-amyloid-induced toxicity. Eur. J. Neurosci. 2006, 23, 55–64. [Google Scholar] [CrossRef] [PubMed]
  43. Pardo-Moreno, T.; González-Acedo, A.; Rivas-Domínguez, A.; García-Morales, V.; García-Cozar, F.J.; Ramos-Rodríguez, J.J.; Melguizo-Rodríguez, L. Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives. Pharmaceutics 2022, 14, 1117. [Google Scholar] [CrossRef] [PubMed]
  44. E Hasselmo, M. The role of acetylcholine in learning and memory. Curr. Opin. Neurobiol. 2006, 16, 710–715. [Google Scholar] [CrossRef]
  45. Khan, H.; Marya; Amin, S.; Kamal, M.A.; Patel, S. Flavonoids as acetylcholinesterase inhibitors: Current therapeutic standing and future prospects. Biomed. Pharmacother. 2018, 101, 860–870. [Google Scholar] [CrossRef]
  46. Grundman, M.; Delaney, P. Antioxidant strategies for Alzheimer’s disease. Proc. Nutr. Soc. 2002, 61, 191–202. [Google Scholar] [CrossRef] [PubMed]
  47. Harman, D. The aging process. Proc. Natl. Acad. Sci. USA 1981, 78, 7124–7128. [Google Scholar] [CrossRef]
  48. Rajalakshmi, P.; Vadivel, V.; Ravichandran, N.; Brindha, P. Investigation on Pharmacognostic Parameters of Sirunagapoo (Mesua ferrea L): A Traditional Indian Herbal Drug. Pharmacogn. J. 2019, 11, 225–230. [Google Scholar] [CrossRef]
  49. Shen, Y.; Song, X.; Li, L.; Sun, J.; Jaiswal, Y.; Huang, J.; Liu, C.; Yang, W.; Williams, L.; Zhang, H.; et al. Protective effects of p-coumaric acid against oxidant and hyperlipidemia-an in vitro and in vivo evaluation. Biomed. Pharmacother. 2019, 111, 579–587. [Google Scholar] [CrossRef] [PubMed]
  50. Velderrain-Rodríguez, G.R.; Torres-Moreno, H.; Villegas-Ochoa, M.A.; Ayala-Zavala, J.F.; Robles-Zepeda, R.E.; Wall-Medrano, A.; González-Aguilar, G.A. Gallic Acid Content and an Antioxidant Mechanism Are Responsible for the Antiproliferative Activity of ‘Ataulfo’ Mango Peel on LS180 Cells. Molecules 2018, 23, 695. [Google Scholar] [CrossRef]
  51. Hardy, J.; Selkoe, D.J. The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics. Science 2002, 297, 353–356. [Google Scholar] [CrossRef]
  52. Blennow, K.; de Leon, M.J.; Zetterberg, H. Alzheimer’s disease. Lancet 2006, 368, 387–403. [Google Scholar] [CrossRef] [PubMed]
  53. Wogulis, M.; Wright, S.; Cunningham, D.; Chilcote, T.; Powell, K.; Rydel, R.E. Nucleation-Dependent Polymerization Is an Essential Component of Amyloid-Mediated Neuronal Cell Death. J. Neurosci. 2005, 25, 1071–1080. [Google Scholar] [CrossRef] [PubMed]
  54. Yatin, S.M.; Varadarajan, S.; Link, C.D.; A Butterfield, D.A. In Vitro and In Vivo Oxidative Stress Associated with Alzheimer’s Amyloid Beta-Peptide (1–42). Neurobiol. Aging 1999, 20, 325–330. [Google Scholar] [CrossRef]
  55. Cardoso, S.M.; Santos, S.; Swerdlow, R.H.; Oliveira, C.R. Functional mitochondria are required for amyloid β-mediated neurotoxicity. FASEB J. 2001, 15, 1439–1441. [Google Scholar] [CrossRef]
  56. Yun, S.H.; Gamkrelidze, G.; Stine, W.B.; Sullivan, P.M.; Pasternak, J.F.; LaDu, M.J.; Trommer, B.L. Amyloid-beta1–42 reduces neuronal excitability in mouse dentate gyrus. Neurosci. Lett. 2006, 403, 162–165. [Google Scholar] [CrossRef] [PubMed]
  57. Hampton, M.B.; Orrenius, S. Dual regulation of caspase activity by hydrogen peroxide: Implications for apoptosis. FEBS Lett. 1997, 414, 552–556. [Google Scholar] [CrossRef]
  58. Pomytkin, I.A. H2O2 Signalling Pathway: A Possible Bridge between Insulin Receptor and Mitochondria. Curr. Neuropharmacol. 2012, 10, 311–320. [Google Scholar] [CrossRef]
  59. Nakajima, Y.; Inokuchi, Y.; Nishi, M.; Shimazawa, M.; Otsubo, K.; Hara, H. Coenzyme Q10 protects retinal cells against oxidative stress in vitro and in vivo. Brain Res. 2008, 1226, 226–233. [Google Scholar] [CrossRef]
  60. Feng, C.; Luo, T.; Zhang, S.; Liu, K.; Zhang, Y.; Luo, Y.; Ge, P. Lycopene protects human SH-SY5Y neuroblastoma cells against hydrogen peroxide-induced death via inhibition of oxidative stress and mitochondria-associated apoptotic pathways. Mol. Med. Rep. 2016, 13, 4205–4214. [Google Scholar] [CrossRef]
  61. Quiroz-Baez, R.; Rojas, E.; Arias, C. Oxidative stress promotes JNK-dependent amyloidogenic processing of normally expressed human APP by differential modification of α-, β- and γ-secretase expression. Neurochem. Int. 2009, 55, 662–670. [Google Scholar] [CrossRef]
  62. Dewachter, I.; Reversé, D.; Caluwaerts, N.; Ris, L.; Kuipéri, C.; Haute, C.V.D.; Spittaels, K.; Umans, L.; Serneels, L.; Thiry, E.; et al. Neuronal Deficiency of Presenilin 1 Inhibits Amyloid Plaque Formation and Corrects Hippocampal Long-Term Potentiation but Not a Cognitive Defect of Amyloid Precursor Protein [V717I] Transgenic Mice. J. Neurosci. 2002, 22, 3445–3453. [Google Scholar] [CrossRef]
  63. De Strooper, B.; Vassar, R.; Golde, T. The secretases: Enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 2010, 6, 99–107. [Google Scholar] [CrossRef] [PubMed]
  64. Cai, H.; Wang, Y.; McCarthy, D.; Wen, H.; Borchelt, D.R.; Price, D.L.; Wong, P.C. BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nat. Neurosci. 2001, 4, 233–234. [Google Scholar] [CrossRef] [PubMed]
  65. Bennett, B.D.; Babu-Khan, S.; Loeloff, R.; Louis, J.-C.; Curran, E.; Citron, M.; Vassar, R. Expression Analysis of BACE2 in Brain and Peripheral Tissues. J. Biol. Chem. 2000, 275, 20647–20651. [Google Scholar] [CrossRef] [PubMed]
  66. Farzan, M.; Schnitzler, C.E.; Vasilieva, N.; Leung, D.; Choe, H. BACE2, A β-Secretase Homolog, Cleaves at the β Site and within the Amyloid-β Region of the Amyloid-β Precursor Protein. Proc. Natl. Acad. Sci. USA 2000, 97, 9712–9717. [Google Scholar] [CrossRef]
  67. Hussain, I.; Powell, D.; Howlett, D.; Chapman, G.; Gilmour, L.; Murdock, P.; Tew, D.; Meek, T.; Chapman, C.; Schneider, K.; et al. ASP1 (BACE2) Cleaves the Amyloid Precursor Protein at the β-Secretase Site. Mol. Cell. Neurosci. 2000, 16, 609–619. [Google Scholar] [CrossRef]
  68. Bodendorf, U.; Danner, S.; Fischer, F.; Stefani, M.; Sturchler-Pierrat, C.; Wiederhold, K.-H.; Staufenbiel, M.; Paganetti, P. Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. J. Neurochem. 2002, 80, 799–806. [Google Scholar] [CrossRef]
  69. Levites, Y.; Amit, T.; Mandel, S.; Youdim, M.B.H. Neuroprotection and neurorescue against Aβ toxicity and PKC-dependent release of non-amyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J. 2003, 17, 1–23. [Google Scholar] [CrossRef]
  70. Li, R.; Lindholm, K.; Yang, L.-B.; Yue, X.; Citron, M.; Yan, R.; Beach, T.; Sue, L.; Sabbagh, M.; Cai, H.; et al. Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer’s disease patients. Proc. Natl. Acad. Sci. USA 2004, 101, 3632–3637. [Google Scholar] [CrossRef]
  71. Iwata, N.; Tsubuki, S.; Takaki, Y.; Watanabe, K.; Sekiguchi, M.; Hosoki, E.; Kawashima-Morishima, M.; Lee, H.-J.; Hama, E.; Sekine-Aizawa, Y.; et al. Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat. Med. 2000, 6, 143–150. [Google Scholar] [CrossRef]
  72. Yasojima, K.; Akiyama, H.; McGeer, E.G.; McGeer, P.L. Reduced neprilysin in high plaque areas of Alzheimer brain: A possible relationship to deficient degradation of β-amyloid peptide. Neurosci. Lett. 2001, 297, 97–100. [Google Scholar] [CrossRef] [PubMed]
  73. Iwata, N.; Tsubuki, S.; Takaki, Y.; Shirotani, K.; Lu, B.; Gerard, N.P.; Gerard, C.; Hama, E.; Lee, H.-J.; Saido, T.C. Metabolic Regulation of Brain Abeta by Neprilysin. Science 2001, 292, 1550–1552. [Google Scholar] [CrossRef] [PubMed]
  74. Shirsat, P.; AR, Z.; Kashikar, R.; Athavale, M.; Athavale, T.; Taware, P.; Saldanha, T.; Kolhe, S.; Tembhurne, S. Subacute toxicity study of the ethanolic extract of Mesua ferrea (L.) flowers in rats. Drug Chem. Toxicol. 2022, 45, 1570–1577. [Google Scholar] [CrossRef]
  75. Ebert, U.; Kirch, W. Scopolamine model of dementia: Electroencephalogram findings and cognitive performance: Scopolamine Model of Dementia. Eur. J. Clin. Investig. 1998, 28, 944–949. [Google Scholar] [CrossRef] [PubMed]
  76. Nunez, J. Morris water maze experiment. J. Vis. Exp. 2008, 897. [Google Scholar] [CrossRef]
  77. Shin, C.Y.; Kim, H.-S.; Cha, K.-H.; Won, D.H.; Lee, J.-Y.; Jang, S.W.; Sohn, U.D. The Effects of Donepezil, an Acetylcholinesterase Inhibitor, on Impaired Learning and Memory in Rodents. Biomol. Ther. 2018, 26, 274–281. [Google Scholar] [CrossRef] [PubMed]
Cimb 45 00259 g001 550
Figure 1. Effect of the MFE extract on hydrogen hydroxide-induced cell death in SH-SY5Y cells. Data are means ± SD (n = 5) and ** p < 0.01 compared to the H2O2-treated group.
Figure 1. Effect of the MFE extract on hydrogen hydroxide-induced cell death in SH-SY5Y cells. Data are means ± SD (n = 5) and ** p < 0.01 compared to the H2O2-treated group.
Cimb 45 00259 g001
Cimb 45 00259 g002 550
Figure 2. Effect of the MFE extract on Aβ-induced cell damage in SH-SY5Y cells. Data are means ± SD (n = 5) and * p < 0.05, ** p < 0.01 compared to the Aβ-treated group.
Figure 2. Effect of the MFE extract on Aβ-induced cell damage in SH-SY5Y cells. Data are means ± SD (n = 5) and * p < 0.05, ** p < 0.01 compared to the Aβ-treated group.
Cimb 45 00259 g002
Cimb 45 00259 g003 550
Figure 3. Protein levels of AD-related protein in SH-SY5Y neuroblastoma cells induced with 250 μM H2O2, with or without pretreatment with MFE extract at 0.1, 1, and 10 µg/mL and N-acetylcysteine (NAC) as standard. Data are means ± SD (n = 3) and ** p < 0.01 compared to the H2O2-treated group.
Figure 3. Protein levels of AD-related protein in SH-SY5Y neuroblastoma cells induced with 250 μM H2O2, with or without pretreatment with MFE extract at 0.1, 1, and 10 µg/mL and N-acetylcysteine (NAC) as standard. Data are means ± SD (n = 3) and ** p < 0.01 compared to the H2O2-treated group.
Cimb 45 00259 g003
Cimb 45 00259 g004 550
Figure 4. Effect of the MFE extract (50, 250, and 500 mg/kg/day) on memory impairment induced by scopolamine in Y-maze test. Reference standard donepezil (3 mg/kg/day). The data were shown as mean ± SEM (n = 6). ## p < 0.01 compared with control group (Sham), ** p < 0.01 compared with scopolamine-treated group.
Figure 4. Effect of the MFE extract (50, 250, and 500 mg/kg/day) on memory impairment induced by scopolamine in Y-maze test. Reference standard donepezil (3 mg/kg/day). The data were shown as mean ± SEM (n = 6). ## p < 0.01 compared with control group (Sham), ** p < 0.01 compared with scopolamine-treated group.
Cimb 45 00259 g004
Cimb 45 00259 g005 550
Figure 5. Effect of the MFE extract (50, 250, and 500 mg/kg/day) on memory impairment induced by scopolamine in Morris Water Maze. Reference standard donepezil (3 mg/kg/day). The data were shown as mean ± SEM (n = 6). ## p < 0.01 compare with control group (Sham), * p < 0.05, ** p < 0.01 compare with scopolamine-treated group.
Figure 5. Effect of the MFE extract (50, 250, and 500 mg/kg/day) on memory impairment induced by scopolamine in Morris Water Maze. Reference standard donepezil (3 mg/kg/day). The data were shown as mean ± SEM (n = 6). ## p < 0.01 compare with control group (Sham), * p < 0.05, ** p < 0.01 compare with scopolamine-treated group.
Cimb 45 00259 g005
Cimb 45 00259 g006 550
Figure 6. HPLC chromatograms of six standards solution (A) and the MFE extract. (B) (1 = gallic acid, 2 = p-coumaric acid, 3 = catechin, 4 = rutin, 5 = ferulic acid, 6 = quercetin).
Figure 6. HPLC chromatograms of six standards solution (A) and the MFE extract. (B) (1 = gallic acid, 2 = p-coumaric acid, 3 = catechin, 4 = rutin, 5 = ferulic acid, 6 = quercetin).
Cimb 45 00259 g006
Table
Table 1. The chemical content and the activities related to AD of the MFE extract.
Table 1. The chemical content and the activities related to AD of the MFE extract.
IndexMFE Extract
(IC50) μg/mL		Trolox
(IC50) μM		Tacrine
(IC50) μM		Qurcumin
(IC50) μM
Total phenolic content, mgGAE/g Extract109.59 ± 2.12NDNDND
Total flavonoid content, mgQE/g Extract43.77 ± 5.92NDNDND
Antioxidant ABTS assay 85.28 ± 3.2264.83 ± 0.77NDND
Antioxidant DPPH assay 35.33 ± 0.6525.00 ± 0.57NDND
AChE inhibitory 242.49 ± 3.53ND0.40 ± 1.3ND
Anti-Aβ aggregation 39.73 ± 1.72NDND3.01 ± 2.35
ND = Not detected.
Table
Table 2. Validation results of the analytical method for determination of gallic acid (1), p-coumaric acid (2), catechin (3), rutin (4), ferulic acid (5), quercetin (6) content in the MFE extract.
Table 2. Validation results of the analytical method for determination of gallic acid (1), p-coumaric acid (2), catechin (3), rutin (4), ferulic acid (5), quercetin (6) content in the MFE extract.
Parameter Compounds
Gallic AcidCoumaric AcidCatechinRutinFerulic AcidQuercetin
LinearityRange (µg/mL)5–3010–6020–10010–6010–6010–60
Coefficient Determination (R2)0.9982 ± 0.000320.9960 ± 0.000490.9978 ± 0.000360.9959 ± 0.000060.9909 ± 0.000700.9926 ± 0.00107
LOD (µg/mL) 0.10.10.20.30.20.5
LOQ (µg/mL) 0.20.50.50.90.71.3
Precision (%RSD)Within day0.19–0.830.69–1.990.54–1.500.22–0.890.25–1.460.67–1.18
Between day0.16–1.100.39–1.320.47–1.960.43–2.740.04–0.490.90–3.14
Accuracy (%)Conc. (Low)102.58101.65107.19109.73107.18101.37
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Plekratoke, K.; Boonyarat, C.; Monthakantirat, O.; Nualkaew, N.; Wangboonskul, J.; Awale, S.; Chulikhit, Y.; Daodee, S.; Khamphukdee, C.; Chaiwiwatrakul, S.; et al. The Effect of Ethanol Extract from Mesua ferrea Linn Flower on Alzheimer’s Disease and Its Underlying Mechanism. Curr. Issues Mol. Biol. 2023, 45, 4063-4079. https://doi.org/10.3390/cimb45050259

AMA Style

Plekratoke K, Boonyarat C, Monthakantirat O, Nualkaew N, Wangboonskul J, Awale S, Chulikhit Y, Daodee S, Khamphukdee C, Chaiwiwatrakul S, et al. The Effect of Ethanol Extract from Mesua ferrea Linn Flower on Alzheimer’s Disease and Its Underlying Mechanism. Current Issues in Molecular Biology. 2023; 45(5):4063-4079. https://doi.org/10.3390/cimb45050259

Chicago/Turabian Style

Plekratoke, Kusawadee, Chantana Boonyarat, Orawan Monthakantirat, Natsajee Nualkaew, Jinda Wangboonskul, Suresh Awale, Yaowared Chulikhit, Supawadee Daodee, Charinya Khamphukdee, Suchada Chaiwiwatrakul, and et al. 2023. "The Effect of Ethanol Extract from Mesua ferrea Linn Flower on Alzheimer’s Disease and Its Underlying Mechanism" Current Issues in Molecular Biology 45, no. 5: 4063-4079. https://doi.org/10.3390/cimb45050259

Article Metrics

Back to TopTop